In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to be looking for bargains all the more intently. On average, the ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

AbbVie has been reporting an earnings decline because its former lead drug, Humira, lost patent-protected market exclusivity ...

Activist investor Starboard has taken a $1 billion stake in Pfizer, according to a report, Super Micro stock surges, and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Here are some of the major companies whose stocks moved on the week’s news.

ETFs such as The Schwab US Dividend ETF can be useful, but a 'DIY' approach can help you outperform. Here are 3 of the best ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...

We provide aggregated data on dividend stocks. On October 8, 2024 ... to be paid on December 27, 2024. Pfizer today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend ...